EP1641927B1
(en)
|
2003-02-18 |
2015-07-08 |
Baylor College of Medicine |
Induced activation in dendritic cells
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20130266551A1
(en)
*
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
WO2008039874A2
(en)
|
2006-09-26 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
WO2008039969A2
(en)
|
2006-09-28 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
JP5779090B2
(ja)
|
2008-04-09 |
2015-09-16 |
マックスサイト インコーポレーティッド |
新規に単離された細胞の治療組成物の操作および送達
|
PL2328923T3
(pl)
|
2008-09-02 |
2016-06-30 |
Cedars Sinai Medical Center |
Epitopy CD133
|
US8415150B2
(en)
*
|
2009-02-24 |
2013-04-09 |
The Trustees Of The University Of Pennsylvania |
Methods for treating progressive multifocal leukoencephalopathy (PML)
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
US20130302276A1
(en)
|
2010-10-22 |
2013-11-14 |
Dana-Farber Cancer Insitute Inc., |
Discovery of regulatory t cells programmed to suppress an immune response
|
EP3305798A1
(en)
*
|
2010-12-09 |
2018-04-11 |
The Trustees of The University of Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
WO2012142213A2
(en)
|
2011-04-15 |
2012-10-18 |
The Johns Hopkins University |
Safe sequencing system
|
WO2013059593A1
(en)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
US9272002B2
(en)
*
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
MX2014010185A
(es)
*
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
CN104159909A
(zh)
*
|
2012-02-22 |
2014-11-19 |
宾夕法尼亚大学董事会 |
产生用于癌症治疗的t细胞持续性群体的组合物和方法
|
EP3093294A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Dll3 modulators and methods of use
|
CA3116051C
(en)
*
|
2012-03-23 |
2023-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
SG11201406414WA
(en)
|
2012-04-11 |
2014-11-27 |
Us Health |
Chimeric antigen receptors targeting b-cell maturation antigen
|
ES2962571T3
(es)
|
2012-05-25 |
2024-03-19 |
Cellectis |
Métodos para modificar células T alogénicas y resistentes a la inmunosupresión para inmunoterapia
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
CA2878856A1
(en)
*
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating car t cells
|
US20160235787A1
(en)
*
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
KR20210149195A
(ko)
*
|
2012-07-13 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
형질도입된 t 세포의 투여 적합성을 평가하는 방법
|
JP2015523386A
(ja)
*
|
2012-07-13 |
2015-08-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
寛容を誘導するために正常b細胞を枯渇させるためのcart19の使用
|
LT4019041T
(lt)
|
2012-07-13 |
2023-04-11 |
The Trustees Of The University Of Pennsylvania |
Toksiškumo, atsirandančio dėl car receptorių priešnavikinio aktyvumo, suvaldymas
|
RU2019126655A
(ru)
*
|
2012-08-20 |
2019-11-12 |
Фред Хатчинсон Кансэр Рисёч Сентер |
Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
|
KR102141259B1
(ko)
*
|
2012-09-04 |
2020-08-05 |
셀렉티스 |
멀티―체인 키메라 항원 수용체 및 그것의 용도들
|
JP6307085B2
(ja)
*
|
2012-09-27 |
2018-04-04 |
ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズThe United States of America,as represented by the Secretary,Department of Health and Human Services |
メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
|
WO2014052545A2
(en)
|
2012-09-28 |
2014-04-03 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
|
US9365641B2
(en)
*
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
*
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
RU2658485C2
(ru)
*
|
2012-10-24 |
2018-06-21 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы м971
|
EP3447495B2
(en)
|
2012-10-29 |
2024-03-13 |
The Johns Hopkins University |
Papanicolaou test for ovarian and endometrial cancers
|
AU2015210373B2
(en)
*
|
2012-12-20 |
2017-04-06 |
Celgene Corporation |
Chimeric antigen receptors
|
AU2013204922B2
(en)
*
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
EP2953475B1
(en)
*
|
2013-02-06 |
2019-07-03 |
Celgene Corporation |
Modified t lymphocytes having improved specificity
|
CA2898474A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
CN105142677B
(zh)
*
|
2013-02-15 |
2019-08-30 |
加利福尼亚大学董事会 |
嵌合抗原受体及其使用方法
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
RS58873B1
(sr)
|
2013-02-22 |
2019-08-30 |
Abbvie Stemcentrx Llc |
Antidll3-antitelo-pbd konjugati i njihova upotreba
|
KR20210108497A
(ko)
|
2013-02-26 |
2021-09-02 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
AU2014225788B2
(en)
*
|
2013-03-05 |
2018-03-29 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
US20160145348A1
(en)
|
2013-03-14 |
2016-05-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
US9944690B2
(en)
|
2013-03-14 |
2018-04-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9499855B2
(en)
*
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9657105B2
(en)
*
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
KR20150128997A
(ko)
|
2013-03-15 |
2015-11-18 |
메모리얼 슬로안-케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
CN111643663A
(zh)
|
2013-03-15 |
2020-09-11 |
细胞基因公司 |
修饰的t淋巴细胞
|
CN113512522A
(zh)
|
2013-03-15 |
2021-10-19 |
普林斯顿大学理事会 |
用于高通量纯化的方法和设备
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US20150064153A1
(en)
|
2013-03-15 |
2015-03-05 |
The Trustees Of Princeton University |
High efficiency microfluidic purification of stem cells to improve transplants
|
CN105264127B
(zh)
|
2013-03-15 |
2019-04-09 |
Gpb科学有限责任公司 |
颗粒的片上微流体处理
|
UY35468A
(es)
*
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
KR102098985B1
(ko)
*
|
2013-05-03 |
2020-04-09 |
오하이오 스테이트 이노베이션 파운데이션 |
Cs1-특이적 키메라 항원 수용체 가공된 면역 작동체 세포
|
EP4119662A1
(en)
|
2013-05-10 |
2023-01-18 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
EP2997141B1
(en)
*
|
2013-05-13 |
2022-10-12 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
WO2014190273A1
(en)
*
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
CA2912389C
(en)
|
2013-06-10 |
2020-01-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
WO2015031771A2
(en)
|
2013-08-30 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
JP6502931B2
(ja)
|
2013-10-11 |
2019-04-17 |
アメリカ合衆国 |
Tem8抗体およびその使用
|
EP3057994B1
(en)
|
2013-10-15 |
2020-09-23 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
ES2741308T3
(es)
*
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
CA2926267C
(en)
*
|
2013-10-17 |
2023-08-01 |
National University Of Singapore |
Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
CN104561069A
(zh)
*
|
2013-10-23 |
2015-04-29 |
深圳先进技术研究院 |
含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
BR112016010716A8
(pt)
|
2013-11-13 |
2020-04-22 |
Novartis Ag |
dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
CA2930587A1
(en)
|
2013-11-25 |
2015-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control hiv infection
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
SG11201604565WA
(en)
|
2013-12-06 |
2016-07-28 |
Us Health |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
WO2015090229A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
EP3808410A1
(en)
*
|
2013-12-20 |
2021-04-21 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
BR112016014156A8
(pt)
|
2013-12-20 |
2023-04-11 |
Hutchinson Fred Cancer Res |
Moléculas efetoras quiméricas etiquetadas e receptores das mesmas
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3094653B1
(en)
*
|
2014-01-13 |
2019-10-23 |
Stephen J. Forman |
Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3105333B1
(en)
*
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
KR102375998B1
(ko)
*
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
AU2015216875B2
(en)
*
|
2014-02-14 |
2021-02-25 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
EP3542816A1
(en)
|
2014-02-14 |
2019-09-25 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
JP6772063B2
(ja)
*
|
2014-02-14 |
2020-10-21 |
ベリカム ファーマシューティカルズ, インコーポレイテッド |
誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
|
MX2016010677A
(es)
|
2014-02-21 |
2017-04-10 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
|
EP3107552B1
(en)
|
2014-02-21 |
2018-03-28 |
Cellectis |
Method for in situ inhibition of regulatory t cells
|
CN103820393B
(zh)
*
|
2014-02-24 |
2016-09-07 |
西比曼生物科技(上海)有限公司 |
工程化cd20靶向性的nkt细胞及其制备方法和应用
|
WO2015131035A1
(en)
|
2014-02-27 |
2015-09-03 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
|
CN104877028A
(zh)
*
|
2014-02-28 |
2015-09-02 |
百奥迈科生物技术有限公司 |
抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用
|
US11885806B2
(en)
|
2014-03-05 |
2024-01-30 |
Autolus Limited |
Method for depleting malignant T-cells
|
CN112094347A
(zh)
*
|
2014-03-05 |
2020-12-18 |
奥托路斯有限公司 |
具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
PL3119807T3
(pl)
|
2014-03-19 |
2019-09-30 |
Cellectis |
Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
|
WO2015143224A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Ambrx, Inc. |
Chimeric antigen receptor-modified t-cells
|
CN110841074B
(zh)
|
2014-03-21 |
2023-07-18 |
艾伯维公司 |
抗-egfr抗体及抗体药物偶联物
|
RU2701341C2
(ru)
*
|
2014-04-03 |
2019-09-25 |
Селлектис |
Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака
|
KR20210107166A
(ko)
*
|
2014-04-07 |
2021-08-31 |
미네르바 바이오테크놀로지 코포레이션 |
항-nme 항체
|
DK3129470T3
(da)
*
|
2014-04-07 |
2021-07-05 |
Novartis Ag |
Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
|
RU2752275C2
(ru)
|
2014-04-10 |
2021-07-26 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Способ и композиции для клеточной иммунотерапии
|
JP6698546B2
(ja)
|
2014-04-14 |
2020-05-27 |
セレクティスCellectis |
癌免疫療法のためのbcma(cd269)特異的キメラ抗原受容体
|
JP6759187B2
(ja)
|
2014-04-23 |
2020-09-23 |
ジュノー セラピューティクス インコーポレイテッド |
養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法
|
CN110938655A
(zh)
|
2014-04-25 |
2020-03-31 |
蓝鸟生物公司 |
Mnd启动子嵌合抗原受体
|
US20170049819A1
(en)
*
|
2014-04-25 |
2017-02-23 |
Bluebird Bio, Inc. |
Kappa/lambda chimeric antigen receptors
|
HUE049514T2
(hu)
|
2014-04-25 |
2020-09-28 |
Bluebird Bio Inc |
Javított eljárások adoptív sejtterápiák kialakítására
|
WO2015167766A1
(en)
*
|
2014-04-29 |
2015-11-05 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
CA2984484C
(en)
*
|
2014-05-02 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
JP2017514522A
(ja)
|
2014-05-02 |
2017-06-08 |
エモリー ユニバーシティー |
ヒト化可変性リンパ球受容体(vlr)および組成物ならびにそれに関連する使用
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションLycera Corporation |
RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
GB2541599B
(en)
*
|
2014-05-14 |
2020-05-20 |
Carsgen Therapeutics Ltd |
Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
AU2015270912B9
(en)
|
2014-06-02 |
2021-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting CD-19
|
ES2846811T3
(es)
|
2014-06-06 |
2021-07-29 |
Bluebird Bio Inc |
Composiciones de células T mejoradas
|
JP2017519502A
(ja)
*
|
2014-06-17 |
2017-07-20 |
セレクティスCellectis |
Cd123特異的多重鎖キメラ抗原受容体
|
GB201506423D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
RU2741120C2
(ru)
|
2014-07-21 |
2021-01-22 |
Новартис Аг |
Лечение рака с использованием химерного антигенного рецептора cll-1
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
BR112017001818A2
(pt)
*
|
2014-07-29 |
2017-11-21 |
Pfizer |
receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer
|
AU2015295349B2
(en)
*
|
2014-07-29 |
2020-09-24 |
Cellectis |
ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
EP3194432B1
(en)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
CA2957958C
(en)
|
2014-08-27 |
2023-10-17 |
Harvey Cantor |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
ES2688035T3
(es)
*
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
US9975959B2
(en)
|
2014-08-29 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
AU2015310897B2
(en)
*
|
2014-09-04 |
2020-03-19 |
Cellectis |
Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
EP3191507A1
(en)
*
|
2014-09-09 |
2017-07-19 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
CN107206071A
(zh)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
Alk抑制剂的联合疗法
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
EP3193933B1
(en)
|
2014-09-17 |
2021-04-28 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd276 antibodies (b7h3)
|
CN107002084B
(zh)
*
|
2014-09-19 |
2021-09-10 |
希望之城公司 |
靶向IL13Rα2的共刺激嵌合抗原受体T细胞
|
LT3200815T
(lt)
|
2014-10-02 |
2021-07-26 |
The Wistar Institute Of Anatomy And Biology |
Būdai ir kompozicijos, skirti vėžio gydymui
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
CA2963327A1
(en)
*
|
2014-10-07 |
2016-04-14 |
Cellectis |
Method for modulating car-induced immune cells activity
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
AU2015329444B2
(en)
*
|
2014-10-09 |
2017-11-23 |
Yamaguchi University |
CAR expression vector and CAR-expressing T cells
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
SG11201703203RA
(en)
*
|
2014-10-20 |
2017-05-30 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
AU2015339744B2
(en)
|
2014-10-31 |
2021-03-25 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in CART cells and uses thereof
|
US11471487B2
(en)
|
2014-10-31 |
2022-10-18 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding T cells
|
WO2016073748A1
(en)
*
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Biomarkers and targets for cancer immunotherapy
|
EP3215534B1
(en)
|
2014-11-05 |
2020-04-15 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
NZ769595A
(en)
|
2014-11-05 |
2023-06-30 |
Juno Therapeutics Inc |
Methods for transduction and cell processing
|
JP2017535284A
(ja)
|
2014-11-05 |
2017-11-30 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
SI3218005T1
(sl)
|
2014-11-12 |
2023-06-30 |
Seagen Inc. |
Z glikanom delujoče spojine, in postopki uporabe
|
CN105601746B
(zh)
*
|
2014-11-21 |
2021-02-19 |
三生国健药业(上海)股份有限公司 |
一种嵌合Fc受体的融合蛋白及其制备方法和应用
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
CN107206025A
(zh)
|
2014-12-03 |
2017-09-26 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的方法和组合物
|
EP4310097A3
(en)
|
2014-12-05 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
CA2969704C
(en)
|
2014-12-05 |
2023-05-02 |
City Of Hope |
Cs1 targeted chimeric antigen receptor-modified t cells
|
MY192065A
(en)
|
2014-12-05 |
2022-07-25 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
|
KR20170108944A
(ko)
|
2014-12-05 |
2017-09-27 |
메모리얼 슬로안-케터링 캔서 센터 |
B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
|
SG10201913937QA
(en)
|
2014-12-05 |
2020-03-30 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
AU2015361261B2
(en)
*
|
2014-12-08 |
2020-03-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD70 chimeric antigen receptors
|
EP3230321B1
(en)
|
2014-12-12 |
2019-08-28 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
EP3234120A4
(en)
|
2014-12-15 |
2018-05-16 |
The Regents of the University of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
WO2016100232A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
PL3237442T3
(pl)
|
2014-12-24 |
2020-02-28 |
Ucl Business Plc |
Komórka
|
EP3240803B1
(en)
|
2014-12-29 |
2021-11-24 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
KR20170128234A
(ko)
|
2015-01-16 |
2017-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1에 특이적인 항체 및 키메라 항원 수용체
|
AU2016212162A1
(en)
|
2015-01-26 |
2017-07-13 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to CD123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
EP3250587B1
(en)
*
|
2015-01-29 |
2020-03-25 |
Regents of the University of Minnesota |
Chimeric antigen receptors, compositions, and methods
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
US10765699B2
(en)
*
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
WO2016130516A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
US20160228544A1
(en)
*
|
2015-02-11 |
2016-08-11 |
Ensysce Biosciences, Inc. |
Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
|
WO2016134371A2
(en)
|
2015-02-20 |
2016-08-25 |
Ohio State Innovation Foundation |
Bivalent antibody directed against nkg2d and tumor associated antigens
|
MA41613A
(fr)
*
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
MX2017010721A
(es)
|
2015-02-24 |
2018-08-28 |
Univ California |
Interruptores transcripcionales activados mediante unión y métodos para su uso.
|
CN107667169B
(zh)
|
2015-02-24 |
2021-10-29 |
得克萨斯州大学系统董事会 |
遗传修饰的t细胞的选择方法
|
US10273280B2
(en)
|
2015-02-27 |
2019-04-30 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
|
US10195272B2
(en)
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
JP6336684B2
(ja)
*
|
2015-03-02 |
2018-06-06 |
イノベイティブ セルラー セラピューティクス シーオー.,エルティディ.Innovative Cellular Therapeutics Co.,Ltd. |
Pd−l1によって誘導される免疫寛容の低減
|
EP3265481B1
(en)
*
|
2015-03-05 |
2024-05-01 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
WO2016149578A1
(en)
|
2015-03-19 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
ES2904573T3
(es)
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
EP3274715A4
(en)
*
|
2015-03-27 |
2018-10-10 |
University of Southern California |
Hla-g as a novel target for car t-cell immunotherapy
|
WO2016161415A2
(en)
*
|
2015-04-02 |
2016-10-06 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/ hvem proteins and methods of use thereof
|
SG10201913158PA
(en)
|
2015-04-03 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
JP6871232B2
(ja)
|
2015-04-06 |
2021-05-12 |
サブドメイン リミテッド ライアビリティ カンパニー |
新規結合ドメイン含有ポリペプチドおよびその使用
|
CN108367057B
(zh)
|
2015-04-06 |
2022-11-22 |
赛通免疫股份有限公司 |
用于胶质母细胞瘤的egfr导向的car疗法
|
KR20170134642A
(ko)
|
2015-04-08 |
2017-12-06 |
노파르티스 아게 |
Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
CN108473957A
(zh)
|
2015-04-17 |
2018-08-31 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
EP3288638A1
(en)
|
2015-04-25 |
2018-03-07 |
The General Hospital Corporation |
Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
|
EP3288569A4
(en)
*
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
WO2016176652A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
EP3288568A4
(en)
*
|
2015-04-30 |
2019-01-02 |
University of Southern California |
Secretory tnt car cell immunotherapy
|
JP7340221B2
(ja)
|
2015-05-01 |
2023-09-07 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア |
グリカン依存性免疫療法分子
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションLycera Corporation |
RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
|
IL310108A
(en)
|
2015-05-06 |
2024-03-01 |
Snipr Tech Ltd |
Changing bacterial populations and microbiota adaptation
|
US10968426B2
(en)
|
2015-05-08 |
2021-04-06 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
US20200316231A1
(en)
*
|
2015-05-10 |
2020-10-08 |
The Trustees Of The University Of Pennsylvania |
Compositions And Methods For Imaging Immune Cells
|
US11253616B2
(en)
|
2017-09-06 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Small molecules for dual function positron emission tomography (PET) and cell suicide switches
|
WO2016180467A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
US20180147271A1
(en)
*
|
2015-05-18 |
2018-05-31 |
Bluebird Bio, Inc. |
Anti-ror1 chimeric antigen receptors
|
FI3298033T4
(fi)
*
|
2015-05-18 |
2023-09-22 |
Tcr2 Therapeutics Inc |
Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
|
WO2016185035A1
(en)
*
|
2015-05-20 |
2016-11-24 |
Cellectis |
Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
JP7197979B2
(ja)
|
2015-05-28 |
2022-12-28 |
カイト ファーマ インコーポレイテッド |
T細胞療法のために患者をコンディショニングする方法
|
AU2016268863B2
(en)
|
2015-05-28 |
2022-06-23 |
Kite Pharma, Inc. |
Diagnostic methods for T cell therapy
|
EP3302547A1
(en)
*
|
2015-05-28 |
2018-04-11 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
WO2016196384A1
(en)
|
2015-05-29 |
2016-12-08 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
EP3660035A1
(en)
|
2015-05-30 |
2020-06-03 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
CA2987992A1
(en)
|
2015-06-04 |
2016-12-08 |
University Of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
SG10202110399WA
(en)
*
|
2015-06-05 |
2021-11-29 |
Novartis Ag |
Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
|
WO2016201124A2
(en)
|
2015-06-09 |
2016-12-15 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
|
AU2016275030B2
(en)
|
2015-06-10 |
2021-12-09 |
Nantkwest, Inc. |
Modified NK-92 cells for treating cancer
|
MX2017016134A
(es)
|
2015-06-11 |
2018-08-15 |
Lycera Corp |
Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
|
US10639329B2
(en)
|
2015-06-12 |
2020-05-05 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
CN105177031B
(zh)
*
|
2015-06-12 |
2018-04-24 |
北京艺妙神州医疗科技有限公司 |
嵌合抗原受体修饰的t细胞及其用途
|
EP3307282A4
(en)
*
|
2015-06-12 |
2019-05-01 |
Immunomedics, Inc. |
TREATMENT OF DISEASES WITH CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (T-CAR) OR NK (CAR-NK) CELL EXPRESSION CONSTRUCTIONS CAR CONSTRUCTIONS
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
DK3310805T3
(da)
|
2015-06-19 |
2021-05-03 |
Sebastian Kobold |
Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin
|
US11655452B2
(en)
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
US11059880B2
(en)
|
2015-06-30 |
2021-07-13 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
|
MA42902A
(fr)
*
|
2015-07-08 |
2018-05-16 |
Univ Johns Hopkins |
Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
|
WO2017011316A1
(en)
*
|
2015-07-10 |
2017-01-19 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
US10493139B2
(en)
*
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
EP3328402A4
(en)
|
2015-07-28 |
2019-04-03 |
The Trustees Of The University Of Pennsylvania |
CHIMERIC ANTIGEN RECEPTORS EXPRESSING MODIFIED MONOCYTES / MACROPHAGES AND USES THEREOF
|
CA2993431A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Nuclease based knockouts of immunological checkpoint genes in immune cells
|
AU2016301932B2
(en)
*
|
2015-08-05 |
2020-02-27 |
CellabMED Inc. |
Chimeric antigen receptor, and T cells in which chimeric antigen receptor is expressed
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
US11286531B2
(en)
|
2015-08-11 |
2022-03-29 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
CN106467906B
(zh)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
构建体、转基因淋巴细胞及其制备方法和用途
|
US10976232B2
(en)
|
2015-08-24 |
2021-04-13 |
Gpb Scientific, Inc. |
Methods and devices for multi-step cell purification and concentration
|
US11890301B2
(en)
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
EP4218777A3
(en)
*
|
2015-08-28 |
2023-08-23 |
The Trustees of the University of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
WO2017040529A1
(en)
*
|
2015-08-31 |
2017-03-09 |
Bluebird Bio, Inc. |
Anti-sialyl tn chimeric antigen receptors
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
WO2017041143A1
(en)
*
|
2015-09-11 |
2017-03-16 |
Ctm@Crc Ltd. |
Chimeric antigen receptors and uses thereof
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
JP2018531229A
(ja)
|
2015-09-18 |
2018-10-25 |
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル |
癌の治療のための抗fugetactic剤の局所的送達
|
AU2016324303A1
(en)
*
|
2015-09-18 |
2018-04-26 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Modified T-cells having anti-fugetactic properties and uses thereof
|
CN108779161A
(zh)
*
|
2015-09-22 |
2018-11-09 |
宾夕法尼亚大学董事会 |
重定向t细胞以治疗hiv感染的方法
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
MX2018003534A
(es)
|
2015-09-25 |
2019-04-25 |
Abvitro Llc |
Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
|
WO2017058752A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
US20180264038A1
(en)
|
2015-09-28 |
2018-09-20 |
Regents Of The University Of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
KR20180056770A
(ko)
*
|
2015-10-06 |
2018-05-29 |
시티 오브 호프 |
Psca로 표적화된 키메라 항원 수용체
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
JP6857360B2
(ja)
*
|
2015-10-08 |
2021-04-14 |
国立大学法人東海国立大学機構 |
キメラ抗原受容体を発現する遺伝子改変t細胞の調製方法
|
WO2017059796A1
(en)
|
2015-10-08 |
2017-04-13 |
Shanghai Sidansai Biotechnology Co., Ltd |
Activation and expansion of t cells
|
CN105153315B
(zh)
*
|
2015-10-09 |
2019-04-02 |
重庆精准生物技术有限公司 |
免疫抑制受体联合肿瘤抗原嵌合受体及其应用
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CN108779162B
(zh)
*
|
2015-10-09 |
2021-12-07 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
CN108474040B
(zh)
*
|
2015-10-09 |
2023-05-16 |
夸登特健康公司 |
使用无细胞dna的基于群体的治疗推荐
|
CN105924530B
(zh)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
|
CN106755023A
(zh)
*
|
2015-10-15 |
2017-05-31 |
中国人民解放军军事医学科学院附属医院 |
带安全开关的嵌合抗原受体免疫细胞及其制备方法与应用
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
EP3362569B1
(en)
|
2015-10-16 |
2021-09-01 |
Ludwig-Maximilians-Universität München |
Cxcr6-transduced t cells for targeted tumor therapy
|
KR20180066237A
(ko)
|
2015-10-19 |
2018-06-18 |
유니버시티 오브 매사추세츠 |
항-암 및 항-염증 치료제 및 이의 방법
|
CN113293131A
(zh)
|
2015-10-20 |
2021-08-24 |
凯德药业股份有限公司 |
制备用于t细胞疗法的t细胞的方法
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
CN108474002B
(zh)
|
2015-10-22 |
2023-05-23 |
朱诺治疗学有限公司 |
用于转导的方法、反应剂盒、反应剂和设备
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
CN105132445B
(zh)
*
|
2015-10-23 |
2018-10-02 |
马健颖 |
一种特异识别肿瘤细胞的受体蛋白、t淋巴细胞及nk细胞
|
KR20180091820A
(ko)
*
|
2015-10-23 |
2018-08-16 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
프로그래밍 가능한 범용 세포 수용체 및 이의 사용 방법
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
CN105384826A
(zh)
*
|
2015-11-19 |
2016-03-09 |
广州熙帝生物科技有限公司 |
表达嵌合抗原受体的脐血有核细胞及其应用
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
CN109152824B
(zh)
*
|
2015-11-27 |
2022-12-06 |
卡瑟里克斯私人有限公司 |
经遗传修饰的细胞及其用途
|
WO2017096327A2
(en)
|
2015-12-03 |
2017-06-08 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against cell therapies
|
EP3383892B1
(en)
|
2015-12-03 |
2022-12-21 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
US20180362975A1
(en)
|
2015-12-04 |
2018-12-20 |
Novartis Ag |
Compositions and methods for immunooncology
|
US11090373B2
(en)
*
|
2015-12-04 |
2021-08-17 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Antigen-specific T cells for inducing immune tolerance
|
MA43377A
(fr)
*
|
2015-12-04 |
2021-05-19 |
Hutchinson Fred Cancer Res |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
WO2017106328A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
WO2017112741A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
US10610527B2
(en)
|
2015-12-22 |
2020-04-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
WO2017114497A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
WO2017120546A1
(en)
|
2016-01-08 |
2017-07-13 |
The Regents Of The University Of California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
GB201600328D0
(en)
|
2016-01-08 |
2016-02-24 |
Univ Oslo Hf |
Anti-CD37 chimeric antigen receptors and immune cells expressing them
|
CN105950645A
(zh)
*
|
2016-01-11 |
2016-09-21 |
灏灵赛奥(天津)生物科技有限公司 |
Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
|
EP3402518A4
(en)
*
|
2016-01-14 |
2019-07-03 |
Memorial Sloan-Kettering Cancer Center |
PEPTIDES SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES, DERIVED FROM FOXP3
|
WO2017123911A1
(en)
*
|
2016-01-15 |
2017-07-20 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
EA201891641A1
(ru)
|
2016-01-21 |
2019-01-31 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
|
EP3405490B1
(en)
|
2016-01-21 |
2021-10-20 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
CN105567640A
(zh)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
一种嵌合抗原受体脂肪干细胞及其制备方法
|
JP2019509275A
(ja)
|
2016-02-23 |
2019-04-04 |
イミューン デザイン コーポレイション |
マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
|
EP3423483A4
(en)
|
2016-03-02 |
2019-08-21 |
Board Of Regents Of the University Of Texas System |
VARIANTS OF HUMAN ENZYME KYNURENINASE HAVING IMPROVED PHARMACOLOGICAL PROPERTIES
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
EP3430130B1
(en)
*
|
2016-03-14 |
2023-01-04 |
Wisconsin Alumni Research Foundation |
Methods of t cell expansion and activation
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
CA3017442A1
(en)
*
|
2016-03-17 |
2017-09-21 |
Yamaguchi University |
Immunocompetent cell and expression vector expressing regulatory factors of immune function
|
US10875927B2
(en)
|
2016-03-18 |
2020-12-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for CD20 immunotherapy
|
JP7048571B2
(ja)
|
2016-03-22 |
2022-04-05 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
毒性を予防または改善するための早期介入法
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN116425876A
(zh)
|
2016-04-01 |
2023-07-14 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
KR20200068750A
(ko)
|
2016-04-01 |
2020-06-15 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
WO2017173410A1
(en)
|
2016-04-01 |
2017-10-05 |
Amgen Inc. |
Chimeric receptors to flt3 and methods of use thereof
|
AU2017240667C1
(en)
*
|
2016-04-01 |
2022-11-24 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
US10654934B2
(en)
|
2016-04-01 |
2020-05-19 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
CN109219445B
(zh)
*
|
2016-04-01 |
2022-08-26 |
上海煦顼技术有限公司 |
嵌合抗原受体修饰细胞治疗癌症的应用
|
CN115094036A
(zh)
|
2016-04-08 |
2022-09-23 |
爱默蕾大学 |
使用基于细胞的疗法治疗癌症和传染病的方法
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
CN106399255B
(zh)
*
|
2016-04-13 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Pd-1 car-t细胞及其制备方法和应用
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
MA43552A
(fr)
|
2016-04-15 |
2018-11-07 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de cd80 et leurs utilisations
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
CN105907719B
(zh)
*
|
2016-04-18 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Anti ROBO1 CAR-T细胞及其制备和应用
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
KR102529012B1
(ko)
|
2016-04-22 |
2023-05-09 |
크라제 메디컬 씨오 리미티드 |
세포성 면역요법을 위한 조성물 및 방법
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
AU2017261380A1
(en)
|
2016-05-06 |
2018-11-22 |
Editas Medicine, Inc. |
Genetically engineered cells and methods of making the same
|
US11261223B2
(en)
*
|
2016-05-11 |
2022-03-01 |
The University Of Chicago |
Methods of treating cancers with CT45 targeted therapies
|
CA3025516A1
(en)
*
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
CA3025523A1
(en)
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
CN105837693A
(zh)
*
|
2016-05-30 |
2016-08-10 |
李斯文 |
一种基于bcma的抗原嵌合受体及其制备方法和应用
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
MX2018014991A
(es)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Terapias adoptivas de celulas como opciones de tratamiento temprano.
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
US11390658B2
(en)
|
2016-06-06 |
2022-07-19 |
St. Jude Children's Research Hospital |
Anti-CD7 chimeric antigen receptor and method of use thereof
|
US20200002421A1
(en)
|
2016-06-08 |
2020-01-02 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CA3027103A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
AU2017279548A1
(en)
|
2016-06-08 |
2018-12-13 |
Precigen, Inc. |
Cd33 specific chimeric antigen receptors
|
JP2019522643A
(ja)
|
2016-06-08 |
2019-08-15 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
EP3468596A2
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
SG10201914119TA
(en)
|
2016-06-08 |
2020-02-27 |
Abbvie Inc |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
CN109562106B
(zh)
|
2016-06-21 |
2023-03-21 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
CN106117367B
(zh)
*
|
2016-06-24 |
2020-02-11 |
安徽未名细胞治疗有限公司 |
一种her-3特异性嵌合抗原受体及其应用
|
EP3474867A4
(en)
|
2016-06-24 |
2020-05-20 |
iCell Gene Therapeutics LLC |
CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CA3026858A1
(en)
|
2016-06-30 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Improved adoptive t-cell therapy
|
KR102382895B1
(ko)
|
2016-07-12 |
2022-04-08 |
카이트 파마 인코포레이티드 |
항원 결합 분자 및 그의 사용 방법
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
KR20190057275A
(ko)
*
|
2016-07-18 |
2019-05-28 |
헬릭스 바이오파마 코포레이션 |
암을 치료하기 위한 암배아 항원 관련 세포 부착 분자 6에 대한 car 면역 세포
|
WO2018017708A1
(en)
*
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
EP3491016A1
(en)
|
2016-07-28 |
2019-06-05 |
Novartis AG |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
CN110088133B
(zh)
*
|
2016-07-29 |
2023-12-08 |
朱诺治疗学股份有限公司 |
抗独特型抗体及相关方法
|
ES2951552T3
(es)
|
2016-07-29 |
2023-10-23 |
Juno Therapeutics Inc |
Polipéptidos inmunomoduladores y composiciones y métodos relacionados
|
CA3031994A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
RU2019105693A
(ru)
|
2016-08-01 |
2020-09-01 |
Новартис Аг |
Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018045177A1
(en)
|
2016-09-01 |
2018-03-08 |
Chimera Bioengineering, Inc. |
Gold optimized car t-cells
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
AU2017319702A1
(en)
|
2016-09-02 |
2019-04-11 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
CN109843922B
(zh)
|
2016-09-02 |
2023-10-03 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
CN109890952A
(zh)
|
2016-09-12 |
2019-06-14 |
朱诺治疗学股份有限公司 |
灌注生物反应器袋装配
|
AU2017332161A1
(en)
|
2016-09-21 |
2019-04-04 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
IL265438B2
(en)
*
|
2016-09-23 |
2023-10-01 |
Univ Southern California |
Chimeric antigen receptors and jewelry and methods for using them
|
EP4353319A3
(en)
|
2016-09-28 |
2024-06-05 |
Atossa Therapeutics, Inc. |
Methods of adoptive cell therapy
|
EP3518972A4
(en)
|
2016-09-28 |
2020-07-22 |
Kite Pharma, Inc. |
ANTIGEN BINDING MOLECULES AND THEIR METHODS OF USE
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
AU2017341048A1
(en)
|
2016-10-07 |
2019-05-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for T-cell receptors reprogramming using fusion proteins
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CN107151654B
(zh)
*
|
2016-10-11 |
2020-05-05 |
深圳宾德生物技术有限公司 |
一种人源t淋巴细胞的培养基及其制备方法和应用
|
CN107936120B
(zh)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
Cd19靶向性的嵌合抗原受体及其制法和应用
|
EP4190335A1
(en)
|
2016-10-13 |
2023-06-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
EP3529359B1
(en)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes for use in therapy
|
EP3529268A1
(en)
|
2016-10-19 |
2019-08-28 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
CA3041284A1
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
KR20190099194A
(ko)
|
2016-10-20 |
2019-08-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
WO2018085731A2
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
WO2018093591A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
SG11201903830TA
(en)
*
|
2016-11-22 |
2019-05-30 |
Nat Univ Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
CA3044355A1
(en)
|
2016-11-23 |
2018-05-31 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
EP3548048A4
(en)
*
|
2016-12-02 |
2020-07-01 |
Cartesian Therapeutics, Inc. |
CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS
|
CA3045355A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
CA3045508A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
WO2018102785A2
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
|
MX2019006438A
(es)
|
2016-12-05 |
2019-11-28 |
Juno Therapeutics Inc |
Produccion de celulas modificadas para terapia de celulas adoptivas.
|
CN108165568B
(zh)
*
|
2016-12-07 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
一种培养CD19CAR-iNKT细胞方法及用途
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
CN108218994A
(zh)
*
|
2016-12-14 |
2018-06-29 |
上海恒润达生生物科技有限公司 |
一种方法培养t记忆干细胞
|
US11278570B2
(en)
|
2016-12-16 |
2022-03-22 |
B-Mogen Biotechnologies, Inc. |
Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
|
US11111483B2
(en)
|
2016-12-16 |
2021-09-07 |
B-Mogen Biotechnologies, Inc. |
Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems and methods
|
CN108276493B
(zh)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
一种嵌合抗原受体及其应用
|
US11447562B2
(en)
|
2017-01-01 |
2022-09-20 |
Chi-Yu Gregory Lee |
RP215 chimeric antigen receptor construct and methods of making and using same
|
EP3565535A4
(en)
|
2017-01-05 |
2020-12-30 |
Fred Hutchinson Cancer Research Center |
SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
|
CN110248677B
(zh)
|
2017-01-05 |
2023-05-16 |
上海煦顼技术有限公司 |
人源化抗cd19抗体及其与嵌合抗原受体的用途
|
EP3346001A1
(en)
*
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合
|
WO2018129336A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
CN108285920A
(zh)
*
|
2017-01-09 |
2018-07-17 |
上海恒润达生生物科技有限公司 |
一种体内检测cart细胞表达的技术及其用途
|
JP7429338B2
(ja)
|
2017-01-10 |
2024-02-08 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のエピジェネティック解析
|
GB201700553D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
CN110494451B
(zh)
*
|
2017-01-13 |
2023-12-01 |
塞尔达拉医疗有限责任公司 |
靶向tim-1的嵌合抗原受体
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108342363B
(zh)
*
|
2017-01-25 |
2021-02-12 |
北京马力喏生物科技有限公司 |
共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
RU2674894C2
(ru)
*
|
2017-01-30 |
2018-12-13 |
Общество с ограниченной ответственностью "ПЛАНТА" |
Новые люциферазы и способы их использования
|
WO2018144597A1
(en)
*
|
2017-01-31 |
2018-08-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of sensitizing cancer cells to immune cell killing
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
CN116693695A
(zh)
|
2017-02-12 |
2023-09-05 |
百欧恩泰美国公司 |
基于hla的方法和组合物及其用途
|
TWI785009B
(zh)
|
2017-02-14 |
2022-12-01 |
美商凱特製藥公司 |
Cd70結合分子及使用彼之方法
|
ES2949364T3
(es)
|
2017-02-17 |
2023-09-28 |
Fred Hutchinson Cancer Center |
Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
|
US11597911B2
(en)
|
2017-02-27 |
2023-03-07 |
Life Technologies Corporation |
Expansion of populations of T cells by the use of modified serum free media
|
CA3053539A1
(en)
|
2017-02-27 |
2018-08-30 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための組成物および方法
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
JP7341900B2
(ja)
*
|
2017-03-03 |
2023-09-11 |
オブシディアン セラピューティクス, インコーポレイテッド |
免疫療法のためのcd19組成物及び方法
|
MX2019010202A
(es)
|
2017-03-03 |
2019-10-02 |
Seattle Genetics Inc |
Compuestos que interactuan con glicano y metodos de uso.
|
US20180280437A1
(en)
|
2017-03-13 |
2018-10-04 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
CN110913690A
(zh)
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
用于低温储存的方法
|
BR112019018747A2
(pt)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
proteínas imunomoduladoras variantes de cd80 e usos das mesmas
|
EP3596115A1
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
FI3596116T3
(fi)
|
2017-03-16 |
2023-11-09 |
Alpine Immune Sciences Inc |
Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
|
AU2018236461A1
(en)
|
2017-03-17 |
2019-09-19 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
US11851659B2
(en)
|
2017-03-22 |
2023-12-26 |
Novartis Ag |
Compositions and methods for immunooncology
|
JP2020515542A
(ja)
|
2017-03-23 |
2020-05-28 |
ザ ジェネラル ホスピタル コーポレイション |
Cxcr4/cxcr7の遮断およびヒトパピローマウイルス関連疾患の治療
|
US10426797B2
(en)
*
|
2017-03-24 |
2019-10-01 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
EP3600356A4
(en)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
CA3057505A1
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
CN110475571B
(zh)
|
2017-04-01 |
2023-04-04 |
Avm生物技术有限责任公司 |
细胞免疫疗法前细胞毒性预调理的替代
|
TW201902493A
(zh)
|
2017-04-03 |
2019-01-16 |
美商凱特製藥公司 |
使用併入最佳化多功能t細胞之嵌合受體t細胞之治療
|
JP7284707B2
(ja)
|
2017-04-07 |
2023-05-31 |
ジュノー セラピューティクス インコーポレイテッド |
前立腺特異的膜抗原(psma)またはその改変型を発現する操作された細胞および関連方法
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
WO2018191722A1
(en)
|
2017-04-14 |
2018-10-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
CA3059584A1
(en)
|
2017-04-14 |
2018-10-18 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
CN108727497A
(zh)
*
|
2017-04-17 |
2018-11-02 |
沈阳美达博生物科技有限公司 |
一种cd19抗体及其应用
|
JP7181219B2
(ja)
|
2017-04-18 |
2022-11-30 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
抗原特異的免疫エフェクター細胞
|
EP3612629A1
(en)
|
2017-04-18 |
2020-02-26 |
The Broad Institute, Inc. |
Compositions for detecting secretion and methods of use
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
CA3059939A1
(en)
|
2017-04-21 |
2018-10-25 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
AR111625A1
(es)
|
2017-04-27 |
2019-07-31 |
Juno Therapeutics Gmbh |
Reactivos de partículas oligoméricas y métodos de uso de los mismos
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
CA3061945A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
CN107226867B
(zh)
*
|
2017-07-25 |
2018-02-06 |
重庆精准生物技术有限公司 |
抗人cd19抗原的嵌合抗原受体及其应用
|
DE112018002302B4
(de)
*
|
2017-05-02 |
2020-10-22 |
Chongqing Precision Biotech Company Limited |
Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung
|
KR20200003913A
(ko)
*
|
2017-05-10 |
2020-01-10 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
CA3062506A1
(en)
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
CN110650975B
(zh)
|
2017-05-15 |
2024-04-05 |
美国卫生和人力服务部 |
双顺反子嵌合抗原受体及其用途
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
BR112019024719A2
(pt)
|
2017-05-24 |
2020-06-16 |
Effector Therapeutics, Inc. |
Composições e métodos para resposta imunológica antitumor aprimorada
|
EP3406733A1
(en)
|
2017-05-24 |
2018-11-28 |
SIB Swiss Institute of Bioinformatics |
Kinase mutants and uses thereof
|
WO2018218137A1
(en)
|
2017-05-25 |
2018-11-29 |
Leidos, Inc. |
Pd-1 and ctla-4 dual inhibitor peptides
|
CN110662831A
(zh)
|
2017-05-26 |
2020-01-07 |
凯德药业股份有限公司 |
制备和使用胚胎间充质祖细胞的方法
|
US11566223B2
(en)
|
2017-06-01 |
2023-01-31 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
WO2018222898A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Mayo Foundation For Medical Education And Research |
System and method for providing clinical outcomes driven expertise for disease treatment
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
KR20200027512A
(ko)
|
2017-06-20 |
2020-03-12 |
엥스띠뛰 퀴리 |
Suv39h1에 결함이 있는 면역 세포
|
AU2018289428A1
(en)
|
2017-06-21 |
2020-02-06 |
The General Hospital Corporation |
Methods and compositions for chimeric antigen receptor targeting cancer cells
|
KR20230169388A
(ko)
|
2017-06-22 |
2023-12-15 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
조절 면역 세포를 제조하기 위한 방법 및 이의 용도
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
AU2018290856A1
(en)
|
2017-06-28 |
2020-01-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
AU2018292181A1
(en)
|
2017-06-30 |
2020-01-23 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
CN107287164A
(zh)
*
|
2017-07-07 |
2017-10-24 |
青岛协和华美医学诊断技术有限公司 |
靶向cd19的嵌合抗原受体t细胞、制备方法及应用
|
CN107365798B
(zh)
*
|
2017-07-13 |
2020-07-14 |
山东省齐鲁细胞治疗工程技术有限公司 |
一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
|
AU2018304173A1
(en)
|
2017-07-17 |
2020-01-30 |
Janssen Biotech, Inc. |
Antigen binding regions against fibronectin type III domains and methods of using the same
|
MX2020000900A
(es)
|
2017-07-29 |
2021-01-08 |
Juno Therapeutics Inc |
Reactivos para expandir celulas que expresan receptores recombinantes.
|
WO2019028051A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
MX2020001575A
(es)
|
2017-08-07 |
2020-11-18 |
Univ Johns Hopkins |
Materiales y métodos para evaluar y tratar el cáncer.
|
AU2018313950A1
(en)
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
US20200239910A1
(en)
|
2017-08-09 |
2020-07-30 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
EP3665270A4
(en)
|
2017-08-10 |
2021-04-21 |
National University of Singapore |
T-LYMPHOCYTES T-LYMPHOCYTE RECEPTOR-DEFICIENT CHEMERICAL ANTIGEN RECEPTOR AND METHODS OF USE
|
AU2018319016B2
(en)
|
2017-08-17 |
2023-08-31 |
Ikena Oncology, Inc. |
AHR inhibitors and uses thereof
|
EP3676403A1
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
US10844353B2
(en)
|
2017-09-01 |
2020-11-24 |
Gpb Scientific, Inc. |
Methods for preparing therapeutically active cells using microfluidics
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
KR20200044973A
(ko)
|
2017-09-15 |
2020-04-29 |
라이프 테크놀로지스 코포레이션 |
세포를 배양 및 팽창시키기 위한 조성물 및 방법
|
EP3681531A1
(en)
|
2017-09-15 |
2020-07-22 |
Kite Pharma, Inc. |
Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
|
CN107557337B
(zh)
*
|
2017-09-15 |
2020-06-26 |
山东兴瑞生物科技有限公司 |
一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
|
JP7281774B2
(ja)
*
|
2017-09-19 |
2023-05-26 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
抗hla-a2抗体及びその使用方法
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
KR20200090151A
(ko)
|
2017-09-20 |
2020-07-28 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
신규한 항-hla-a2 항체 및 이의 용도
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的系统、方法和组合物
|
EP3684803A1
(en)
|
2017-09-22 |
2020-07-29 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
IL273432B
(en)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
AU2018338192B2
(en)
|
2017-09-22 |
2022-03-03 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
EP3688143A4
(en)
*
|
2017-09-26 |
2021-09-22 |
Longwood University |
PD1 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS IMMUNOTHERAPY
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
EP3687575A4
(en)
*
|
2017-09-29 |
2021-06-30 |
National Health Research Institutes |
METHODS AND COMPOSITIONS FOR INCREASING SURVIVAL AND FUNCTIONALITY OF ANTITUMOR AND ANTIVIRUS T CELLS
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
EP3694875A1
(en)
|
2017-10-09 |
2020-08-19 |
Wisconsin Alumni Research Foundation |
Antibodies targeting glioblastoma stem-like cells and methods of use thereof
|
KR20230020022A
(ko)
|
2017-10-10 |
2023-02-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
JP2021501570A
(ja)
|
2017-10-18 |
2021-01-21 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
AU2018351000B2
(en)
|
2017-10-18 |
2023-11-30 |
Alpine Immune Sciences, Inc. |
Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
|
BR112020007493A2
(pt)
|
2017-10-18 |
2020-10-27 |
Kite Pharma, Inc. |
métodos de administrar imunoterapia com receptor de antígeno quimérico
|
CN109694854B
(zh)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技(上海)有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
US20210030793A1
(en)
*
|
2017-10-26 |
2021-02-04 |
St. Jude Children's Research Hospital, Inc. |
Methods and compositions for treating cd33+ cancers and improving in vivo persistence of chimeric antigen receptor t cells
|
WO2019084427A1
(en)
|
2017-10-27 |
2019-05-02 |
Kite Pharma, Inc. |
T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
BR112020008478A2
(pt)
|
2017-11-01 |
2020-10-20 |
Editas Medicine, Inc. |
métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
CN117756946A
(zh)
|
2017-11-03 |
2024-03-26 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
CN111556893A
(zh)
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
CN111601823A
(zh)
*
|
2017-11-07 |
2020-08-28 |
德克萨斯大学体系董事会 |
用car-t或car-nk细胞在癌症治疗中靶向lilrb4
|
JP2021502094A
(ja)
|
2017-11-10 |
2021-01-28 |
ジュノー セラピューティクス インコーポレイテッド |
閉鎖系極低温容器
|
US11802163B2
(en)
|
2017-11-10 |
2023-10-31 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-3 or mesothelin
|
US20210363260A1
(en)
|
2017-11-13 |
2021-11-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
AU2018369639A1
(en)
|
2017-11-14 |
2020-04-23 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
MX2020004935A
(es)
|
2017-11-14 |
2020-09-25 |
Arcellx Inc |
Terapias con celulas inmunitarias multifuncionales.
|
RU2020119365A
(ru)
|
2017-11-15 |
2021-12-13 |
Новартис Аг |
Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
CA3083118A1
(en)
*
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
CN109837244A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
CA3122010A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Coare Holdings, Inc. |
Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
|
KR20200109308A
(ko)
|
2017-12-08 |
2020-09-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법을 위한 표현형 마커 및 관련 방법
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
CA3084445A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
CA3085765A1
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
US11661439B2
(en)
|
2017-12-17 |
2023-05-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide hydrogels and use thereof
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
WO2019123340A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
CN108018312B
(zh)
*
|
2017-12-20 |
2019-09-10 |
上海优卡迪生物医药科技有限公司 |
一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
SG11202005912PA
(en)
|
2017-12-26 |
2020-07-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
CN109970866B
(zh)
*
|
2017-12-28 |
2022-10-04 |
上海细胞治疗研究院 |
一种cd28双向激活共刺激分子受体及其用途
|
CN109970864A
(zh)
*
|
2017-12-28 |
2019-07-05 |
上海细胞治疗研究院 |
一种双向激活共刺激分子受体及其用途
|
CN109971712B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
JP2021509903A
(ja)
*
|
2018-01-05 |
2021-04-08 |
マックスサイト インコーポレーティッド |
癌の長期car処置
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
US11919937B2
(en)
|
2018-01-09 |
2024-03-05 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
JP2021510540A
(ja)
*
|
2018-01-11 |
2021-04-30 |
イノベイティブ セルラー セラピューティクス インク.Innovative Cellular Therapeutics Inc. |
修飾細胞の増幅およびその応用
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
KR20200110356A
(ko)
|
2018-01-15 |
2020-09-23 |
화이자 인코포레이티드 |
키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
|
CA3089051A1
(en)
|
2018-01-22 |
2019-07-25 |
Endocyte, Inc. |
Methods of use for car t cells
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
CN111918972A
(zh)
|
2018-01-31 |
2020-11-10 |
朱诺治疗学股份有限公司 |
评估存在或不存在有复制能力的病毒的方法和试剂
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
WO2019152957A1
(en)
|
2018-02-02 |
2019-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
US20210087511A1
(en)
*
|
2018-02-09 |
2021-03-25 |
Global Life Sciences Solutions Usa Llc |
Bioprocessing methods for cell therapy
|
US20230183313A1
(en)
*
|
2018-02-11 |
2023-06-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
CN110157677A
(zh)
*
|
2018-02-12 |
2019-08-23 |
深圳宾德生物技术有限公司 |
一种靶向性t淋巴细胞及其制备方法和应用
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
TWI796596B
(zh)
|
2018-02-13 |
2023-03-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
EP3752531A1
(en)
|
2018-02-14 |
2020-12-23 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
CN112534044A
(zh)
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
CA3091478A1
(en)
|
2018-02-17 |
2019-08-22 |
Flagship Pioneering Innovations V, Inc. |
Compositions and methods for membrane protein delivery
|
WO2019173324A1
(en)
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
WO2019175328A1
(en)
|
2018-03-14 |
2019-09-19 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Bh4pathwayactivationandusethereoffortreatingcancer
|
BR112020018658A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imu-noterapia aprimorada
|
CA3093915A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
RU2020135966A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
Способы получения клеток, экспрессирующих рекомбинантный рецептор, и родственные композиции
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
CA3093888A1
(en)
|
2018-04-06 |
2019-10-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
UY38182A
(es)
|
2018-04-10 |
2019-10-31 |
Amgen Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
TWI784324B
(zh)
|
2018-04-12 |
2022-11-21 |
美商凱特製藥公司 |
利用腫瘤微環境之特性之嵌合受體t細胞治療
|
WO2019197678A1
(en)
|
2018-04-13 |
2019-10-17 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
WO2019200252A1
(en)
|
2018-04-13 |
2019-10-17 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
US20210079384A1
(en)
|
2018-04-13 |
2021-03-18 |
The Johns Hopkins University |
Non-invasive detection of response to a targeted therapy
|
EP3781179A4
(en)
|
2018-04-16 |
2022-11-09 |
Board of Regents, The University of Texas System |
HUMAN KINURENINASE ENZYMES AND USES THEREOF
|
AU2019255196A1
(en)
|
2018-04-16 |
2020-11-12 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
US10869888B2
(en)
*
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
KR102251028B1
(ko)
|
2018-04-18 |
2021-05-12 |
앱클론(주) |
스위치 분자 및 스위처블 키메라 항원 수용체
|
WO2019204496A1
(en)
*
|
2018-04-19 |
2019-10-24 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating melanoma with a chimeric antigen receptor
|
JP7242702B2
(ja)
|
2018-04-19 |
2023-03-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
SI3784666T1
(sl)
|
2018-04-24 |
2022-07-29 |
Merck Patent Gmbh |
Antiproliferacijske spojine in njihove uporabe
|
IL278122B2
(en)
|
2018-04-24 |
2024-01-01 |
Vertex Pharma |
Petridinon compounds and their uses
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP3813885A4
(en)
|
2018-05-02 |
2022-01-12 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS AND METHODS OF PHOSPHOLIPASE-A2 RECEPTOR CHIMERA AUTOANTIBODY RECEPTOR T CELLS
|
AU2019261986A1
(en)
|
2018-05-03 |
2020-11-26 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (CAR) T cell therapy and a kinase inhibitor
|
CN108753774B
(zh)
*
|
2018-05-03 |
2021-03-30 |
山东省齐鲁细胞治疗工程技术有限公司 |
干扰il-6表达的cd19-car-t细胞及其应用
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
US20210087530A1
(en)
|
2018-05-08 |
2021-03-25 |
Life Technologies Corporation |
Compositions and methods for culturing and expanding cells
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
CA3099152C
(en)
|
2018-05-14 |
2023-10-24 |
Gilead Sciences, Inc. |
Mcl-1 inhibitors
|
KR20210045953A
(ko)
|
2018-05-18 |
2021-04-27 |
더 존스 홉킨스 유니버시티 |
암의 평가 및/또는 치료를 위한 무 세포 dna
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN108715859B
(zh)
*
|
2018-05-31 |
2021-08-03 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
靶向cd22的嵌合抗原受体及其应用
|
US20200003758A1
(en)
|
2018-06-01 |
2020-01-02 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
BR112020024601A2
(pt)
*
|
2018-06-01 |
2021-04-06 |
Mayo Foundation For Medical Education And Research |
Materiais e métodos para tratamento do câncer
|
KR20210016390A
(ko)
|
2018-06-01 |
2021-02-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
KR20190141511A
(ko)
*
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CN112543808A
(zh)
|
2018-06-21 |
2021-03-23 |
比莫根生物科技公司 |
增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
US20210155941A1
(en)
|
2018-06-22 |
2021-05-27 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
EP4234030A3
(en)
|
2018-07-13 |
2023-10-18 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
EP3825404A4
(en)
|
2018-07-17 |
2022-04-13 |
Noile-Immune Biotech, Inc. |
CAR CONTAINING ANTI-GPC3 SINGLE STRAND ANTIBODY
|
EA202190304A1
(ru)
|
2018-07-18 |
2022-01-21 |
Эмджен Инк. |
Химерные рецепторы к steap1 и способы их применения
|
BR112021000919A2
(pt)
|
2018-07-19 |
2021-04-27 |
Regeneron Pharmaceuticals, Inc. |
receptores de antígenos quiméricos com especificidade bcma e usos dos mesmos
|
CN108949759B
(zh)
*
|
2018-07-23 |
2021-06-01 |
合肥一兮生物科技有限公司 |
敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
|
SG11202101014XA
(en)
|
2018-08-02 |
2021-02-25 |
Kite Pharma Inc |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
MX2021001519A
(es)
|
2018-08-09 |
2021-05-27 |
Juno Therapeutics Inc |
Metodos para valorar acidos nucleicos integrados.
|
JP2021533746A
(ja)
|
2018-08-09 |
2021-12-09 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞およびその組成物を生成するための方法
|
EP3835320A4
(en)
*
|
2018-08-10 |
2022-06-01 |
Eutilex Co., Ltd. |
BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
CN110856724B
(zh)
*
|
2018-08-24 |
2022-05-27 |
杭州康万达医药科技有限公司 |
包含核酸及car修饰的免疫细胞的治疗剂及其应用
|
KR20220036908A
(ko)
|
2018-08-28 |
2022-03-23 |
보르 바이오파마 인크. |
유전자 조작된 조혈 줄기 세포 및 그의 용도
|
CN112930393A
(zh)
|
2018-08-28 |
2021-06-08 |
福瑞德哈金森癌症研究中心 |
结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物
|
US20220348682A1
(en)
|
2018-08-30 |
2022-11-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
BR112021003305A2
(pt)
|
2018-08-31 |
2021-05-25 |
Novartis Ag |
métodos para produzir células que expressam receptor de antígeno quimérico
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
JP2022500674A
(ja)
|
2018-09-11 |
2022-01-04 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞組成物のマススペクトロメトリー分析のための方法
|
US20220177587A1
(en)
|
2018-09-19 |
2022-06-09 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
CA3155291A1
(en)
|
2018-09-24 |
2020-04-02 |
The Medical College Of Wisconsin, Inc. |
Anti-cd30 antibodies and methods of use
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
*
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
EA202190926A1
(ru)
|
2018-10-01 |
2021-06-25 |
Эдисет Био, Инк. |
Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
BR112021007690A2
(pt)
|
2018-10-22 |
2021-08-10 |
Shanghai GenBase Biotechnology Co., Ltd. |
anticorpo anti-cldn18.2 e uso do mesmo
|
JP2022505679A
(ja)
|
2018-10-23 |
2022-01-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ny-eso-1 t細胞受容体およびそれらの使用の方法
|
CN112955435A
(zh)
|
2018-10-24 |
2021-06-11 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
WO2020086989A1
(en)
*
|
2018-10-25 |
2020-04-30 |
Innovative Cellular Therapeutics CO., LTD. |
Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
US20210388389A1
(en)
|
2018-10-30 |
2021-12-16 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
LT3873903T
(lt)
|
2018-10-31 |
2024-05-10 |
Gilead Sciences, Inc. |
Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
CN113646335A
(zh)
|
2018-11-01 |
2021-11-12 |
朱诺治疗学股份有限公司 |
使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
|
AU2019374790A1
(en)
|
2018-11-06 |
2021-05-27 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered T cells
|
WO2020097346A1
(en)
*
|
2018-11-07 |
2020-05-14 |
Unum Therapeutics Inc. |
ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
|
CN109467604A
(zh)
*
|
2018-11-07 |
2019-03-15 |
南京卡提医学科技有限公司 |
嵌合抗原受体DAP12-T2A-CD8α-CD19scFv-TREM1及其用途
|
CN109503717A
(zh)
*
|
2018-11-07 |
2019-03-22 |
南京卡提医学科技有限公司 |
嵌合抗原受体DAP12-T2A-CD8α-CD19scfv-NKp44及其用途
|
WO2020097403A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
JP2022507453A
(ja)
|
2018-11-14 |
2022-01-18 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
T細胞送達のためのフソソーム組成物
|
EP3880238A1
(en)
|
2018-11-16 |
2021-09-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
WO2020106621A1
(en)
|
2018-11-19 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
KR20210096648A
(ko)
|
2018-11-29 |
2021-08-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
CN113260633A
(zh)
|
2018-12-05 |
2021-08-13 |
豪夫迈·罗氏有限公司 |
用于癌症免疫疗法的诊断方法和组合物
|
WO2020114491A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for immunotherapy
|
BR112021011063A2
(pt)
|
2018-12-10 |
2021-08-31 |
Amgen Inc. |
Transposase piggybac mutada
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
CN113412117A
(zh)
|
2018-12-12 |
2021-09-17 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3670530A1
(en)
|
2018-12-18 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
WO2020132586A1
(en)
|
2018-12-21 |
2020-06-25 |
Neon Therapeutics, Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
AU2020205000A1
(en)
*
|
2019-01-06 |
2021-06-17 |
Abintus Bio, Inc. |
Car T Cell methods and constructs
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
CN113329792A
(zh)
|
2019-02-15 |
2021-08-31 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
EP3924387A2
(en)
|
2019-02-15 |
2021-12-22 |
University Of Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
AU2020229806A1
(en)
|
2019-02-25 |
2021-07-29 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
MX2021010288A
(es)
*
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
CA3131908A1
(en)
|
2019-03-01 |
2020-09-10 |
Allogene Therapeutics, Inc. |
Dll3 targeting chimeric antigen receptors and binding agents
|
MX2021010670A
(es)
|
2019-03-05 |
2021-11-12 |
Nkarta Inc |
Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
|
JP7350872B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
3’3’-環状ジヌクレオチドおよびそのプロドラッグ
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
WO2020182681A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
AU2020235865A1
(en)
|
2019-03-08 |
2021-09-23 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
AU2020242284A1
(en)
|
2019-03-19 |
2021-09-16 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy for the treatment of cancer
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
MA55565A
(fr)
|
2019-04-05 |
2022-02-09 |
Kymera Therapeutics Inc |
Agents de dégradation de stat et leurs utilisations
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
KR20220004028A
(ko)
|
2019-04-26 |
2022-01-11 |
알로젠 테라퓨틱스 인코포레이티드 |
동종 car t 세포를 제조하는 방법
|
DK3959235T3
(da)
|
2019-04-26 |
2023-10-16 |
Allogene Therapeutics Inc |
Rituximab-resistente kimære antigenreceptorer og anvendelser deraf
|
SG11202112032WA
(en)
|
2019-04-30 |
2021-11-29 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
CN114025788A
(zh)
|
2019-05-01 |
2022-02-08 |
朱诺治疗学股份有限公司 |
从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
TW202108150A
(zh)
|
2019-05-03 |
2021-03-01 |
美商凱特製藥公司 |
投與嵌合抗原受體免疫療法之方法
|
WO2020224606A1
(zh)
|
2019-05-07 |
2020-11-12 |
亘喜生物科技(上海)有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
AU2020279371A1
(en)
|
2019-05-22 |
2021-12-23 |
Leidos, Inc. |
LAG 3 binding peptides
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
US20220251538A1
(en)
|
2019-05-23 |
2022-08-11 |
Matjaz Vogelsang |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
EP4023230A4
(en)
*
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIBODY CLEAVAGE SITE BINDING MOLECULE
|
BR112021024404A2
(pt)
|
2019-06-07 |
2022-04-19 |
Juno Therapeutics Inc |
Cultura de célula t automatizada
|
WO2020252405A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
MA56206A
(fr)
|
2019-06-12 |
2022-04-20 |
Juno Therapeutics Inc |
Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie
|
WO2020257823A2
(en)
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
TGF-β RECEPTORS AND METHODS OF USE
|
WO2020264019A1
(en)
|
2019-06-24 |
2020-12-30 |
Children's Hospital Los Angeles |
Bcl11b overexpression to enhance human thymopoiesis and t cell function
|
BR112021026376A2
(pt)
|
2019-06-25 |
2022-05-10 |
Gilead Sciences Inc |
Proteínas de fusão flt3l-fc e métodos de uso
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えad35ベクター及び関連遺伝子治療改善
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
WO2021011907A1
(en)
|
2019-07-18 |
2021-01-21 |
Gpb Scientific, Inc. |
Ordered processing of blood products to produce therapeutically active cells
|
MX2022000922A
(es)
|
2019-07-23 |
2022-05-03 |
Mnemo Therapeutics |
Celulas inmunes defectuosas para suv39h1.
|
WO2021016585A1
(en)
|
2019-07-24 |
2021-01-28 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
CN110305849B
(zh)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
稳定表达car的t细胞及其制备方法与应用
|
GB201911066D0
(en)
|
2019-08-02 |
2019-09-18 |
Achilles Therapeutics Ltd |
T cell therapy
|
JP2022543702A
(ja)
*
|
2019-08-09 |
2022-10-13 |
エイ2・バイオセラピューティクス・インコーポレイテッド |
ヘテロ接合性の喪失に応答する細胞表面受容体
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
KR20220073738A
(ko)
|
2019-08-30 |
2022-06-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 분류를 위한 기계 학습 방법
|
AU2020343407A1
(en)
|
2019-09-02 |
2022-03-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunotherapy targeting tumor neoantigenic peptides
|
EP4025698A1
(en)
|
2019-09-03 |
2022-07-13 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
US20210062150A1
(en)
|
2019-09-03 |
2021-03-04 |
Allogene Therapeutics, Inc. |
Methods of preparing t cells for t cell therapy
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
EP4028523A1
(en)
|
2019-09-09 |
2022-07-20 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
US20220332780A1
(en)
|
2019-09-10 |
2022-10-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
US20220347216A1
(en)
*
|
2019-09-13 |
2022-11-03 |
Ohio State Innovation Foundation |
Nk cell immunotherapy compositions, methods of making and methods of using same
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
EP4032907A4
(en)
|
2019-09-20 |
2023-07-05 |
Shanghai Genbase Biotechnology Co., Ltd. |
BCMA-TARGETING CHEMERA ANTIGENIC ANTIBODIES AND RECEPTOR
|
WO2021055915A1
(en)
*
|
2019-09-20 |
2021-03-25 |
The University Of North Carolina At Chapel Hill |
Modified t cells and methods of preparing the same
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
KR102287180B1
(ko)
*
|
2019-10-01 |
2021-08-09 |
충북대학교 산학협력단 |
Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
CA3153197A1
(en)
|
2019-10-03 |
2021-04-08 |
Ryan T. Gill |
Crispr systems with engineered dual guide nucleic acids
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
KR20220085796A
(ko)
|
2019-10-18 |
2022-06-22 |
포티 세븐, 인코포레이티드 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
EP4048304A1
(en)
|
2019-10-22 |
2022-08-31 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
EP4048696A1
(en)
|
2019-10-23 |
2022-08-31 |
Kite Pharma, Inc. |
Anti-idiotypic antigen binding molecules and methods of use thereof
|
CN110679588A
(zh)
*
|
2019-10-23 |
2020-01-14 |
厦门生命互联科技有限公司 |
一种嵌合抗原受体t细胞冻存介质及用途
|
TWI717880B
(zh)
|
2019-10-24 |
2021-02-01 |
中國醫藥大學附設醫院 |
Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
KR20220101641A
(ko)
|
2019-10-30 |
2022-07-19 |
주노 테라퓨틱스 게엠베하 |
세포 선택 및/또는 자극 장치 및 사용 방법
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
US20220403002A1
(en)
|
2019-11-01 |
2022-12-22 |
Kyoto Prefectural Public University Corporation |
B-cell antibody receptor and use thereof
|
BR112022007548A2
(pt)
|
2019-11-07 |
2022-07-12 |
Juno Therapeutics Inc |
Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
JP2023503098A
(ja)
|
2019-11-20 |
2023-01-26 |
ジーアイ・セル・インコーポレイテッド |
T細胞培養用培地組成物及びこれを用いたt細胞の培養方法
|
MX2022006308A
(es)
|
2019-11-26 |
2022-06-22 |
Ikena Oncology Inc |
Derivados de carbazol polimorfos y usos de los mismos.
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
KR20220132527A
(ko)
|
2019-12-06 |
2022-09-30 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 악성 종양을 치료하기 위한 세포 요법과 연관된 독성 및 반응과 관련된 방법
|
AU2020395319A1
(en)
|
2019-12-06 |
2022-07-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to BCMA-targeted binding domains and related compositions and methods
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
TW202136242A
(zh)
|
2019-12-23 |
2021-10-01 |
美商凱麥拉醫療公司 |
Smarca降解劑及其用途
|
KR20220131918A
(ko)
|
2019-12-24 |
2022-09-29 |
카나 바이오사이언스, 인코포레이션 |
다이아실글리세롤 키나제 조절 화합물
|
JP7088902B2
(ja)
*
|
2019-12-27 |
2022-06-21 |
クレージュ メディカル カンパニー,リミテッド |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球
|
CN115209996A
(zh)
|
2019-12-28 |
2022-10-18 |
Gpb科学有限公司 |
用于处理颗粒和细胞的微流体盒
|
CN113150167A
(zh)
*
|
2020-01-22 |
2021-07-23 |
中国人民解放军总医院第五医学中心 |
一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
|
IL294715A
(en)
|
2020-01-23 |
2022-09-01 |
Childrens Medical Ct Corp |
Inducible t-cell differentiation from human pluripotent stem cells
|
US20230060095A1
(en)
|
2020-01-24 |
2023-02-23 |
Regeneron Pharmaceuticals, Inc. |
Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
|
AU2021209940A1
(en)
|
2020-01-24 |
2022-08-04 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 형질도입 방법
|
WO2021155897A1
(en)
|
2020-02-03 |
2021-08-12 |
MVZ Prof. Niendorf Pathologie Hamburg-West GmbH |
Marker set for the diagnosis and treatment of cancer
|
KR20220152220A
(ko)
|
2020-02-12 |
2022-11-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cd19-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도
|
IL295381A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
|
US11692038B2
(en)
|
2020-02-14 |
2023-07-04 |
Gilead Sciences, Inc. |
Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
BR112022017148A2
(pt)
|
2020-02-27 |
2022-11-08 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
JP2023515211A
(ja)
|
2020-02-27 |
2023-04-12 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
CN111269326A
(zh)
*
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
NPM1c陽性がんの免疫療法のための組成物および方法
|
MX2022011080A
(es)
|
2020-03-10 |
2023-01-04 |
Massachusetts Inst Technology |
Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas.
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
JP2023518423A
(ja)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス, インコーポレイテッド |
Mdm2分解剤およびそれらの使用
|
JP2023521663A
(ja)
|
2020-03-31 |
2023-05-25 |
サナ バイオテクノロジー,インコーポレイテッド |
標的化脂質粒子及び組成物ならびにその使用
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
US20230340040A1
(en)
*
|
2020-04-14 |
2023-10-26 |
St. Jude Children's Research Hospital, Inc. |
Chimeric myd88 receptors
|
US20210324331A1
(en)
*
|
2020-04-15 |
2021-10-21 |
Amgen Inc. |
Process for generating genetically engineered autologous t cells
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
MX2022013530A
(es)
|
2020-04-28 |
2023-02-01 |
Juno Therapeutics Inc |
Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.
|
US20230226110A1
(en)
|
2020-04-28 |
2023-07-20 |
Achilles Therapeutics Uk Limited |
T cell therapy
|
IL297327A
(en)
|
2020-05-01 |
2022-12-01 |
Gilead Sciences Inc |
4,2-deoxypyrimidine compounds that inhibit cd73
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
MX2022013898A
(es)
|
2020-05-05 |
2023-02-09 |
Regeneron Pharma |
Car que comprende cd28 zeta y cd3 zeta.
|
WO2021228999A1
(en)
|
2020-05-12 |
2021-11-18 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
CN115835873A
(zh)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
用于产生表达重组受体的供体分批细胞的方法
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
WO2021231954A1
(en)
*
|
2020-05-15 |
2021-11-18 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
US20230212256A1
(en)
|
2020-05-21 |
2023-07-06 |
Board Of Regents, The University Of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021240240A1
(en)
|
2020-05-27 |
2021-12-02 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CA3184807A1
(en)
|
2020-06-04 |
2021-12-09 |
Carisma Therapeutics Inc. |
Novel constructs for chimeric antigen receptors
|
WO2021244654A1
(en)
*
|
2020-06-05 |
2021-12-09 |
Nanjing Legend Biotech Co., Ltd. |
Activation induced cytokine production in immune cells
|
JP2023530238A
(ja)
|
2020-06-08 |
2023-07-14 |
ヤンセン バイオテツク,インコーポレーテツド |
キメラ抗原発現免疫細胞のインビトロ腫瘍殺傷活性を決定するための細胞ベースのアッセイ
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
KR102297396B1
(ko)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
|
AU2021316727A1
(en)
|
2020-07-30 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immune cells defective for SOCS1
|
EP4188947A2
(en)
|
2020-07-31 |
2023-06-07 |
Leidos, Inc. |
Lag3 binding peptides
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20230324408A1
(en)
|
2020-08-05 |
2023-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
EP4196568A1
(en)
|
2020-08-13 |
2023-06-21 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
KR20230044537A
(ko)
|
2020-08-13 |
2023-04-04 |
예일 유니버시티 |
원하는 표현형을 갖는 car t 세포의 조작 및 선택을 위한 조성물 및 방법
|
KR20230084470A
(ko)
|
2020-08-14 |
2023-06-13 |
카이트 파마 인코포레이티드 |
면역 세포 기능의 향상
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
IL300497A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Compositions and methods for treating CEACAM-positive cancer
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
EP4204545A2
(en)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T cells with improved functionality
|
WO2022046840A1
(en)
*
|
2020-08-26 |
2022-03-03 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Hybrid allosteric receptor-engineered stem cells
|
AU2021361844A1
(en)
|
2020-10-12 |
2023-06-15 |
Leidos, Inc. |
Immunomodulatory peptides
|
EP4228648A1
(en)
*
|
2020-10-16 |
2023-08-23 |
Neonc Technologies, Inc. |
Combination of poh and remdesivir for treatment of cns infections
|
EP4237854A1
(en)
|
2020-10-28 |
2023-09-06 |
Kite Pharma, Inc. |
Flow cytometric method for characterization of t-cell impurities
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
IL302728A
(en)
|
2020-11-13 |
2023-07-01 |
Catamaran Bio Inc |
Genetically modified natural killer cells and methods of using them
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combined treatments with cells expressing chimeric antigens (vehicle)
|
CN112195250A
(zh)
*
|
2020-11-20 |
2021-01-08 |
山东省医学科学院附属医院 |
一种qPCR试剂盒及应用
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス,インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
CN116745319A
(zh)
|
2020-12-24 |
2023-09-12 |
凯德药业股份有限公司 |
前列腺癌嵌合抗原受体
|
CN117396607A
(zh)
|
2020-12-30 |
2024-01-12 |
阿劳诺斯治疗公司 |
包含多顺反子表达盒的重组载体及其使用方法
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
JP2024502599A
(ja)
|
2021-01-10 |
2024-01-22 |
カイト ファーマ インコーポレイテッド |
T細胞療法
|
TW202241488A
(zh)
|
2021-01-11 |
2022-11-01 |
英商拜斯科技技術開發有限公司 |
治療癌症之方法
|
CA3204161A1
(en)
|
2021-01-11 |
2022-07-14 |
Jagesh Vijaykumar SHAH |
Use of cd8-targeted viral vectors
|
EP4277934A1
(en)
|
2021-01-14 |
2023-11-22 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
US20240115607A1
(en)
|
2021-01-26 |
2024-04-11 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
AU2022214547A1
(en)
*
|
2021-01-27 |
2023-08-17 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Bi-specific car t cells for b cell malignancies
|
JP2024506831A
(ja)
|
2021-01-28 |
2024-02-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群を治療するための組成物及び方法
|
CA3204357A1
(en)
|
2021-01-28 |
2022-08-04 |
Todd LUMAN |
Methods for transducing immune cells
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
TW202241469A
(zh)
|
2021-02-20 |
2022-11-01 |
美商凱特製藥公司 |
免疫療法
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
JP2024512337A
(ja)
|
2021-03-05 |
2024-03-19 |
シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド |
抗cldn6抗体およびその使用
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
KR20230172630A
(ko)
|
2021-03-11 |
2023-12-22 |
므네모 테라퓨틱스 |
종양 네오 항원성 펩타이드
|
WO2022189639A1
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
US20220289815A1
(en)
|
2021-03-11 |
2022-09-15 |
Kite Pharma, Inc. |
Immune cell function
|
KR20240006721A
(ko)
|
2021-03-11 |
2024-01-15 |
엥스띠뛰 퀴리 |
막 형질 전환 네오 안티젠 펩타이드
|
JPWO2022196719A1
(ru)
|
2021-03-17 |
2022-09-22 |
|
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
EP4314814A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
BR112023019847A2
(pt)
|
2021-03-29 |
2023-11-07 |
Juno Therapeutics Inc |
Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
|
WO2022212384A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
GB202109886D0
(en)
|
2021-07-08 |
2021-08-25 |
Achilles Therapeutics Uk Ltd |
Assay
|
WO2022214835A1
(en)
|
2021-04-09 |
2022-10-13 |
Achilles Therapeutics Uk Limited |
Batch release assay for pharmaceutical products relating to t cell therapies
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
WO2022221126A1
(en)
|
2021-04-16 |
2022-10-20 |
Kite Pharma, Inc. |
Methods and systems for scheduling a patient-specific immunotherapy procedure
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
AU2022258832A1
(en)
|
2021-04-16 |
2023-10-19 |
Celgene Corporation |
Combination therapies with bcma-directed t cell therapy
|
JP2024514624A
(ja)
|
2021-04-16 |
2024-04-02 |
カイト ファーマ インコーポレイテッド |
Taci/bcma二重結合分子
|
CA3214280A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
T cell therapy in patients who have had prior stem cell transplant
|
EP4326286A2
(en)
*
|
2021-04-23 |
2024-02-28 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
TW202309269A
(zh)
|
2021-04-27 |
2023-03-01 |
日商武田藥品工業股份有限公司 |
重組抗原呈現細胞
|
AU2022271212A1
(en)
|
2021-05-04 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
EP4334341A2
(en)
|
2021-05-06 |
2024-03-13 |
Juno Therapeutics GmbH |
Methods for stimulating and transducing t cells
|
CA3217354A1
(en)
|
2021-05-14 |
2022-11-17 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用FLT3L—Fc融合蛋白之方法
|
EP4340851A1
(en)
|
2021-05-19 |
2024-03-27 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
WO2022251120A2
(en)
|
2021-05-24 |
2022-12-01 |
Kite Pharma, Inc. |
Chimeric antigen receptor
|
WO2022251434A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Emory University |
Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy
|
EP4347797A1
(en)
|
2021-05-27 |
2024-04-10 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
CN117642420A
(zh)
|
2021-05-28 |
2024-03-01 |
萨那生物科技公司 |
含有截短的狒狒内源性逆转录病毒(BaEV)包膜糖蛋白的脂质颗粒及相关方法和用途
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
CN117730100A
(zh)
|
2021-06-08 |
2024-03-19 |
凯德药业股份有限公司 |
Gpc3结合分子
|
CA3223311A1
(en)
|
2021-06-18 |
2022-12-22 |
Andrea BARGHETTI |
Compositions and methods for targeting, editing or modifying human genes
|
EP4359511A1
(en)
|
2021-06-22 |
2024-05-01 |
Achilles Therapeutics UK Limited |
A method for producing antigen-specific t cells
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
AU2022298639A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3220923A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
EP4363558A1
(en)
|
2021-07-01 |
2024-05-08 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
AU2022301201A1
(en)
|
2021-07-02 |
2024-01-18 |
Kite Pharma, Inc. |
A method for identifying variants in gene products from gene constructs used in cell therapy applications
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
EP4370544A2
(en)
|
2021-07-14 |
2024-05-22 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
CA3224974A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Albert Ruzo Matias |
Polycistronic vectors for cell-based therapies
|
WO2023004300A2
(en)
*
|
2021-07-19 |
2023-01-26 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
|
US20230190799A1
(en)
*
|
2021-07-21 |
2023-06-22 |
City Of Hope |
Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
|
CA3225306A1
(en)
|
2021-07-30 |
2023-02-02 |
Kite Pharma, Inc. |
Monitoring and management of cell therapy-induced toxicities
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向cd4之病毒載體之用途
|
AU2022324040A1
(en)
|
2021-08-04 |
2024-02-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
WO2023019128A1
(en)
*
|
2021-08-09 |
2023-02-16 |
The Trustees Of The University Of Pennyslvania |
Optimizing t cell differentiation state with micrornas
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
TW202323521A
(zh)
|
2021-08-20 |
2023-06-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
WO2023025788A1
(en)
|
2021-08-24 |
2023-03-02 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Il-10 expressing cells for enhanced cancer immunotherapies
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
AU2022349103A1
(en)
|
2021-09-27 |
2024-03-28 |
Sotio Biotech Inc. |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
CA3232254A1
(en)
|
2021-10-18 |
2023-04-27 |
Kite Pharma, Inc. |
Signaling domains for chimeric antigen receptors
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
WO2023077030A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
CA3237201A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
US20230242508A1
(en)
|
2021-12-22 |
2023-08-03 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
EP4215245A1
(en)
|
2022-01-19 |
2023-07-26 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
|
WO2023139269A1
(en)
|
2022-01-21 |
2023-07-27 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023154890A2
(en)
*
|
2022-02-11 |
2023-08-17 |
Fred Hutchinson Cancer Center |
Chimeric antigen receptors binding steap1
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023159001A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
TW202340457A
(zh)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
同種異體治療細胞
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ikaros鋅指家族降解劑及其用途
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
GB202204386D0
(en)
|
2022-03-28 |
2022-05-11 |
Cambridge Entpr Ltd |
Engineered immune cell platform
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
TW202400138A
(zh)
|
2022-04-21 |
2024-01-01 |
美商基利科學股份有限公司 |
Kras g12d調節化合物
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
US20230392119A1
(en)
|
2022-05-27 |
2023-12-07 |
Kite Pharma, Inc. |
Compositions and methods for preparing engineered lymphocytes for cell therapy
|
US20240000844A1
(en)
|
2022-05-27 |
2024-01-04 |
Kite Pharma, Inc. |
Non-viral delivery of cell therapy constructs
|
WO2023240143A1
(en)
|
2022-06-09 |
2023-12-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy cross reference to related applications
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2023242343A1
(en)
|
2022-06-15 |
2023-12-21 |
Immunoscape Pte. Ltd. |
Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024033879A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified cells
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024044670A1
(en)
|
2022-08-26 |
2024-02-29 |
Kite Pharma, Inc. |
Improving immune cell function
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024073583A1
(en)
|
2022-09-30 |
2024-04-04 |
Caribou Biosciences, Inc. |
Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
WO2024092152A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Improving efficacy and durable response of immunotherapy
|
WO2024092145A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Expedited administration of engineered lymphocytes
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
US20240158869A1
(en)
|
2022-10-28 |
2024-05-16 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
WO2024097314A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
WO2024107646A1
(en)
|
2022-11-14 |
2024-05-23 |
Caribou Biosciences, Inc. |
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
|